Credit Suisse Ag Cure Vac N.V. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Cure Vac N.V. stock. As of the latest transaction made, Credit Suisse Ag holds 129,787 shares of CVAC stock, worth $329,658. This represents 0.0% of its overall portfolio holdings.

Number of Shares

129,787

Previous 303,859 57.29%

Holding current value

$329,658

Previous $1.28 Million 69.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.94 - $4.34 $511,771 - $755,472	-174,072 Reduced 57.29%	129,787 $393,000
Q4 2023 Feb 08, 2024	SELL	$3.96 - $6.41 $2,665 - $4,313	-673 Reduced 0.22%	303,859 $1.28 Million
Q3 2023 Nov 13, 2023	BUY	$6.5 - $10.77 $50,576 - $83,801	7,781 Added 2.62%	304,532 $2.08 Million
Q2 2023 Aug 11, 2023	BUY	$6.69 - $12.25 $335,416 - $614,178	50,137 Added 20.33%	296,751 $3.09 Million
Q1 2023 May 10, 2023	BUY	$6.38 - $12.5 $304,887 - $597,350	47,788 Added 24.04%	246,614 $1.72 Million
Q4 2022 Feb 13, 2023	BUY	$5.75 - $8.5 $193,297 - $285,744	33,617 Added 20.35%	198,826 $1.2 Million
Q3 2022 Nov 10, 2022	BUY	$7.48 - $15.24 $405,685 - $826,556	54,236 Added 48.87%	165,209 $1.3 Million
Q2 2022 Aug 12, 2022	BUY	$13.18 - $19.41 $744,340 - $1.1 Million	56,475 Added 103.63%	110,973 $1.51 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $206,352 - $493,817	14,009 Added 34.6%	54,498 $1.07 Million
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $354,296 - $506,647	10,507 Added 35.04%	40,489 $1.39 Million
Q3 2021 Nov 12, 2021	BUY	$49.26 - $74.5 $494,570 - $747,980	10,040 Added 50.35%	29,982 $1.64 Million
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $1.13 Million - $2.54 Million	19,942 New	19,942 $1.47 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $476M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account